Ticagrelor Ticagrelor Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca. Ticagrelor is an antagonist of the P2Y receptor. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high
Moronic acid Moronic acid Moronic acid (3-oxoolean-18-en-28-oic acid) is a natural triterpene. Moronic acid can be extracted from "Rhus javanica", a sumac plant traditionally believed to hold medicinal applications. The molecule has also been extracted from Mistletoe ("Phoradendron reichenbachianum"). Bevirimat, a derivative of the related triterpenoid betulinic acid, is under development as an anti-HIV drug; however, moronic acid has shown better antiviral profiles "in vitro" than bevirimat. A particular moronic acid derivative showed potent anti-HIV activity with EC values of 0.0085 μM against NL4-3, 0.021 μM against PI-R (a multiple protease inhibitor resistant strain), and 0.13 μM against FHR-2 (an HIV strain